Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MET233 in Adults With Obesity or Overweight
NCT07022977Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2024
- Primary completion
- Apr 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MET-233 in obesity (8 arms), sponsored by Pfizer. Primary endpoint: Occurrence of Treatment Emergent Adverse Events at Day 239. Started Nov 2024; status: completed.
02
Drugs
MET-233
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07022977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07022977.